Literature DB >> 16618513

Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury with cholestasis.

Florian Bihl1, Urban Emmenegger, Jürg Reichen, Klaus A Neftel, Arthur Zimmermann, Andreas Cerny.   

Abstract

Macrophage activating syndrome (MAS) is a rare hematological disorder associated with uncontrolled systemic T-cell activation. Persistent fever, fatigue and hepatosplenomegaly are frequent clinical manifestations, whereas hyperferritinemia, elevated serum lactate dehydrogenase levels and cytopenia are key criteria for the diagnosis of MAS. The nature of liver pathology in MAS has been partially elucidated but destructive biliary lesions have been rarely described. This report illustrates four cases of MAS developing marked cholestasis, leading to one case of biliary cirrhosis necessitating liver transplantation. Histologically, liver involvement was characterized in all cases by acute lobular hepatitis, marked hepatocyte apoptosis and small bile duct injury similar to the vanishing bile duct syndrome. Immuno-histological studies showed that the inflammatory changes and bile duct lesions were dominated by the presence of activated macrophages and T-cells, in particular CD8+ lymphocytes, and in part NK-cells. These findings suggest that in MAS, various T-cell triggers such as infection, autoimmune disease and malignancy might result in the release of cytokines, which in turn activate macrophages to trigger a systemic acute phase response and local tissue damage. This communication suggests that a macrophage, T- and NK-cell network is operational in the pathogenesis of the cholangiocyte, hepatocyte and sinus endothelial cell damage in MAS.

Entities:  

Mesh:

Year:  2006        PMID: 16618513     DOI: 10.1016/j.jhep.2006.03.003

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  2 in total

Review 1.  Pediatric acute liver failure of undetermined cause: A research workshop.

Authors:  Estella M Alonso; Simon P Horslen; Edward M Behrens; Edward Doo
Journal:  Hepatology       Date:  2017-01-06       Impact factor: 17.425

2.  Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist.

Authors:  Scott Canna; Jennifer Frankovich; Gloria Higgins; Michael R Narkewicz; S Russell Nash; J Roger Hollister; Jennifer B Soep; Leonard L Dragone
Journal:  Pediatr Rheumatol Online J       Date:  2009-12-22       Impact factor: 3.054

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.